Drug intelligence / Profile preview

KR23343

Development stage: Phase 1
Lead developer: Jiangxi Kerui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KR23343 is an investigational small molecule inhibitor of the urate transporter 1 (URAT1), also known as SLC22A12, currently under development by Jiangxi Kvvit Pharmaceutical Co., Ltd. The drug is primarily intended for the treatment of hyperuricemia and gout. By selectively inhibiting URAT1 in the proximal tubules of the kidney, KR23343 blocks the reabsorption of uric acid from the urine back into the bloodstream, thereby promoting uric acid excretion and reducing serum urate levels. As of early 2024, it is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on KR23343.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR23343.

Explore the full profile